A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2011
12/01/2011	US20110294779 Novel imidazopyridines
12/01/2011	US20110294772 Use of cyclosquaramide compounds as anti-tumour agents
12/01/2011	US20110294764 2-METHYLENE-19,26-NOR-(20S)-1alpha-HYDROXYVITAMIN D3
12/01/2011	US20110294757 Polar lipid mixtures, their preparation and uses
12/01/2011	US20110294756 Gamma secretase modulators
12/01/2011	US20110294742 Degradable clostridial toxins
12/01/2011	US20110294741 Use of compounds in the treatment of tau-induced cytotoxicities
12/01/2011	US20110294740 Treatment of amyloidoses using myelin basic protein and fragments thereof
12/01/2011	US20110294739 Use of the engrailed homeodomain protein as anxiolytic
12/01/2011	US20110294738 Pthr1 receptor compounds
12/01/2011	US20110294734 Pharmaceutical compositions comprising tgf-beta 1 inhibitor peptides
12/01/2011	US20110294720 Apratoxin therapeutic agents: mechanism and methods of treatment
12/01/2011	US20110294717 Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers
12/01/2011	US20110293733 Self-assembling nanoparticle drug delivery system
12/01/2011	US20110293730 Polylactide nanoparticles
12/01/2011	US20110293729 Novel composition based on gamma-hydroxybutyric acid
12/01/2011	US20110293725 Chimeric therapeutics, compositions, and methods for using same
12/01/2011	US20110293718 Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same
12/01/2011	US20110293716 Pharmaceutical formulation containing ibuprofen and codeine
12/01/2011	US20110293715 Pharmaceutical Formulation and Process for Its Preparation
12/01/2011	US20110293702 Compounds and Methods for the Treatment of Inflammatory Diseases of the CNS
12/01/2011	US20110293701 Multivalent synthetic nanocarrier vaccines
12/01/2011	US20110293699 Hydrogel implants with varying degrees of crosslinking
12/01/2011	US20110293688 Hydrogel implants with varying degrees of crosslinking
12/01/2011	US20110293673 Oral film-form base and oral film-form preparation
12/01/2011	US20110293663 Pharmaceutical botulinum toxin compositions
12/01/2011	US20110293635 Composition and methods for modulating toll-like receptor activity
12/01/2011	US20110293631 Mast cell markers and prevention, diagnosis, and therapy for chronic pelvic pain syndrome
12/01/2011	US20110293612 Method for the Treatment of Neurodegenerative Diseases
12/01/2011	US20110293611 Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
12/01/2011	US20110293610 Antibodies that immunospecifically bind to b lymphocyte stimulator protein
12/01/2011	US20110293603 Amino acid sequences directed against multitarget scavenger receptors and polypeptides
12/01/2011	US20110293599 Method for modulating muscle differentiation or regeneration
12/01/2011	US20110293595 Prophylactic and therapeutic treatment of Alzheimer's Disease, neuro-degenerative diseases, protein aggregation diseases, Parkinson's Disease and amyloid diseases, using phytic acid and phytate
12/01/2011	US20110293578 Use of Stem Cells to Prevent Neuronal Dieback
12/01/2011	US20110293576 Mesenchymal stromal cell populations and methods of isolating and using same
12/01/2011	US20110293571 Method for vector delivery
12/01/2011	US20110293564 2-morpholino-pyrido[3,2-d]pyrimidines
12/01/2011	US20110293557 Conjugates for the administration of biologically active compounds
12/01/2011	US20110293556 Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia
12/01/2011	US20110293554 Recombinant human g-csf dimer and use thereof for the treatment of neurological diseases
12/01/2011	US20110293536 Buccal, polar and non-polar spray containing zolipidem
12/01/2011	US20110293535 Composition for buccal absorption of nicotine for the purpose of smoking cessation
12/01/2011	US20110293520 New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
12/01/2011	DE102010017130A1 Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung Hybrid compound, use thereof and process for their preparation
12/01/2011	CA2800910A1 Pharmaceutical dosage form containing an antipsychotic agent
12/01/2011	CA2800688A1 Recombinant human g-csf dimer and use thereof for the treatment of neurological diseases
12/01/2011	CA2800618A1 Heteroaryl compounds and methods of use thereof
12/01/2011	CA2800384A1 Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
12/01/2011	CA2800251A1 Compositions and methods for reduction of mercury toxicity
12/01/2011	CA2800103A1 Pyrazole compounds as sigma receptor inhibitors
12/01/2011	CA2799966A1 Substituted-6-methylnicotinamides as mglur5 positive allosteric modulators
12/01/2011	CA2799203A1 Nicotinic receptor non-competitive antagonists
12/01/2011	CA2798419A1 8-hydroxy-quinoline derivatives
11/2011
11/30/2011	EP2390248A1 Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
11/30/2011	EP2389937A1 Medicinal composition for improving brain function
11/30/2011	EP2389936A1 Aminaphtone for use in the treatment and/or prevention of migraine
11/30/2011	EP2389932A1 Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
11/30/2011	EP2389382A1 Amino-heterocyclic compounds used as pde9 inhibitors
11/30/2011	EP2389380A1 N-oxides of diazabicyclononyl pyrimidine derivatives and their medical use
11/30/2011	EP2389379A1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
11/30/2011	EP2389378A1 Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
11/30/2011	EP2389371A2 Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use
11/30/2011	EP2389350A1 Methods for making valerenic acid derivatives and their use
11/30/2011	EP2389187A1 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
11/30/2011	EP2389182A1 Treatment of neurotrophic factor mediated disorders
11/30/2011	EP2389181A1 Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use
11/30/2011	EP2389175A1 Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
11/30/2011	EP2310383B1 Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
11/30/2011	EP2307420B1 Nalmefene di-ester prodrugs
11/30/2011	EP2231629B1 Modulators for amyloid beta
11/30/2011	EP2229408B1 Peptide derived from neurotensin receptor 3 and use thereof in the treatment of psychiatric diseases
11/30/2011	EP2217583B1 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
11/30/2011	EP2156833B1 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
11/30/2011	EP1938824B1 Medicine, food and drink or feed containing sphingomyelin
11/30/2011	EP1879613B1 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
11/30/2011	EP1841433B1 Composition for treating central nervous system disorders
11/30/2011	EP1702626B1 Screening method for gamma-secretase inhibitors
11/30/2011	EP1633735B1 Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics
11/30/2011	EP1613368B1 Carboxamide spirohydantoin cgrp receptor antagonists
11/30/2011	CN1961879B 组成石杉碱甲鼻用原位凝胶喷雾剂的药物组合物、其制备方法及用途 Huperzine A composition in situ gel nasal sprays a pharmaceutical composition, methods for their preparation and use
11/30/2011	CN1849138B 作为选择性ngf途径抑制剂的人抗ngf中和抗体 Ngf pathway inhibitors as selective human anti ngf neutralizing antibodies
11/30/2011	CN102264743A Mlk抑制剂及其使用方法 Mlk inhibitors and methods of use
11/30/2011	CN102264735A 制备帕潘立酮以及它的草酸盐的一步方法 -Step process for preparing paliperidone and its oxalate
11/30/2011	CN102264731A 1,2,4-二唑衍生物及其治疗用途 1,2,4-oxadiazole derivatives and their therapeutic use
11/30/2011	CN102264728A 用于调节ire1、src和abl活性的方法和组合物 The method used to adjust ire1, src and abl activity and composition
11/30/2011	CN102264707A 新型双环型杂环化合物 Novel bicyclic heterocyclic compounds
11/30/2011	CN102264375A 用于预防或治疗糖尿病多发性周围神经病变的小牛血去蛋白制剂 Calf serum for the prevention or treatment of diabetic peripheral neuropathy to multiple protein preparations
11/30/2011	CN102264361A 预防或减少癌发生或氧化性应激的方法 The method of preventing or reducing cancer or oxidative stress
11/30/2011	CN102260728A 一种蜂王浆多肽及其用途 Polypeptides, and uses one kind of jelly
11/30/2011	CN102260623A 解酒祛湿护肝保健酒及其制备方法 Liver health wine hangover dampness and its preparation method
11/30/2011	CN102260349A 用于治疗和预防阿尔茨海默病的抗Aβ31-35抗体及其制备方法 Anti Aβ31-35 antibody treatment and prevention of Alzheimer's disease and its preparation method
11/30/2011	CN102260344A 缺失型人β干扰素及其重组制备 Deficient recombinant human β-interferon and its preparation
11/30/2011	CN102260343A 重组人g-csf二聚体在治疗神经损伤疾病中的用途 Recombinant human g-csf dimer in the treatment of nerve injury diseases in
11/30/2011	CN102260290A 喹喏啉酮类化合物及其在制备精神病药物中的用途 Quinoxalin-ketones and their use in the preparation of psychiatric drugs
11/30/2011	CN102260270A N-(2-甲基呋喃[2，3-d]嘧啶-4-基)丙烯酰胺、其制备方法及其用途 N- (2- methyl-furo [2,3-d] pyrimidin-4-yl) acrylamide, their preparation and their use
11/30/2011	CN102260266A 吡唑并[3,4-d]嘧啶酮类化合物及其在制备磷酸二酯酶Ⅸ抑制剂中的应用 Pyrazolo [3,4-d] pyrimidine-ketone compounds and its application in the preparation of phosphoric acid Ⅸ PDE inhibitor
11/30/2011	CN102260246A 低毒性cb1受体抑制剂、其制备方法及其在制备戒毒、减肥或治疗糖尿病药物中的应用 Low toxicity cb1 receptor inhibitors, their preparation and their treatment in the preparation, diet or medicine for the treatment of diabetes
11/30/2011	CN102260242A 甲磺酸伊马替尼多晶型物及其药用组合物 Imatinib mesylate polymorphs and pharmaceutical compositions
11/30/2011	CN102258759A 祛风止头痛的配方及使用方法 Headache, chills and formulations and methods of use only

1 ... 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 ... 1833